CJC-1295 vs Sermorelin

Overview

This comparison separates CJC-1295 and Sermorelin for reference—not product selection.

CJC-1295: Short-acting growth hormone-releasing hormone analogue studied in growth hormone research.

Sermorelin: GHRH analogue formerly approved for diagnosing growth hormone deficiency, withdrawn commercially.

Differences

• Both appear in Growth hormone & endocrine research literature, but mechanistic framing differs.
• The useful distinction is research question and receptor context—not relative potency or practical ranking.

Mechanism

CJC-1295: Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows…

Sermorelin: Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary ax…

Pharmacology

CJC-1295: Pharmacokinetic detail should be read from primary literature.

Sermorelin: Pharmacokinetic detail should be read from primary literature.

Research

CJC-1295: Growth hormone & endocrine research: Restores natural GH pulsatility patterns in aging individuals.

Sermorelin: Growth hormone & endocrine research: 1.26kg lean mass increase documented in elderly men with improved muscle strength tests.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/16352683/
• pubmed.ncbi.nlm.nih.gov/17018654/
• pubmed.ncbi.nlm.nih.gov/15817669/
• pubmed.ncbi.nlm.nih.gov/16822960/
• pubmed.ncbi.nlm.nih.gov/19386527/
• pubmed.ncbi.nlm.nih.gov/2877535/
• pubmed.ncbi.nlm.nih.gov/8772599/
• pubmed.ncbi.nlm.nih.gov/9141536/

Questions